Skip to main content
. Author manuscript; available in PMC: 2023 Nov 28.
Published in final edited form as: Adv Pharmacol. 2023 Feb 24;97:229–255. doi: 10.1016/bs.apha.2023.01.002

Fig. 3.

Fig. 3

20-HETE increases myocardial ischemia and it impairs coronary collateral growth in the heart. Illustration highlighting the role of 20-HETE in the rat model of metabolic syndrome (JCR) as a driver of inflammation, endothelial dysfunction, apoptosis and neutrophil infiltration blocking the generation of coronary collateral growth across collateral-dependent zones (CZ) compared to normal zones (NZ). The pharmacological antagonism of 20-HETE via 20-SOLA restores the generation of coronary collateral growth and alleviates the heart from the pro-inflammatory bioactions associated with 20-HETE.